Cargando…

Cardiac adverse events associated with quetiapine: Disproportionality analysis of FDA adverse event reporting system

OBJECTIVE: Quetiapine, an atypical second‐generation antipsychotic drug, is approved for treatment of schizophrenia, bipolar disorder, and depression. Due to the limitations of clinical trials, the association between quetiapine and rare cardiac adverse events (AEs) is still unclear. This study is t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shu, Yamin, Ding, Yiling, Liu, Lulu, Zhang, Qilin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10401141/ https://www.ncbi.nlm.nih.gov/pubmed/37032639 http://dx.doi.org/10.1111/cns.14215

Ejemplares similares

Post-Marketing Safety Concerns With Secukinumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System
por: Shu, Yamin, et al.
Publicado: (2022)

Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system
por: Shu, Yamin, et al.
Publicado: (2023)

A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS)
por: Zou, Shu-peng, et al.
Publicado: (2023)

A Real-World Disproportionality Analysis of Olaparib: Data Mining of the Public Version of FDA Adverse Event Reporting System
por: Shu, Yamin, et al.
Publicado: (2022)

Musculoskeletal Adverse Events Associated with PCSK9 Inhibitors: Disproportionality Analysis of the FDA Adverse Event Reporting System
por: Ding, Lingqing, et al.
Publicado: (2022)

Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system
por: Shu, Yamin, et al.
Publicado: (2022)

Neurological Adverse Events Associated With Esketamine: A Disproportionality Analysis for Signal Detection Leveraging the FDA Adverse Event Reporting System
por: Guo, Haoning, et al.
Publicado: (2022)

Corrigendum: Neurological adverse events associated with esketamine: A disproportionality analysis for signal detection leveraging the FDA adverse event reporting system
por: Guo, Haoning, et al.
Publicado: (2022)

Cardiac arrhythmias associated with immune checkpoint inhibitors: A comprehensive disproportionality analysis of the FDA adverse event reporting system
por: Wang, Feifei, et al.
Publicado: (2022)

1407. Disproportionality Analysis of Safety with Nafcillin and Oxacillin with the FDA Adverse Event Reporting System (FAERS)
por: Timbrook, Tristan T, et al.
Publicado: (2018)

Proarrhythmia associated with antiarrhythmic drugs: a comprehensive disproportionality analysis of the FDA adverse event reporting system
por: Wang, Feifei, et al.
Publicado: (2023)

Bullous Pemphigoid and Diabetes medications: A disproportionality analysis based on the FDA Adverse Event Reporting System
por: Huang, Liting, et al.
Publicado: (2021)

A real-world disproportionality analysis of apalutamide: data mining of the FDA adverse event reporting system
por: Fang, Zhihong, et al.
Publicado: (2023)

Disproportionality analysis of quinolone safety in children using data from the FDA adverse event reporting system (FAERS)
por: Kong, Wenqiang, et al.
Publicado: (2023)

Using disproportionality analysis to explore the association between periostitis and triazole antifungals in the FDA Adverse Event Reporting System Database
por: Li, Hailong, et al.
Publicado: (2023)

Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database
por: Liu, Lulu, et al.
Publicado: (2022)

Comparison of Quetiapine Abuse and Misuse Reports to the FDA Adverse Event Reporting System With Other Second-Generation Antipsychotics
por: Evoy, Kirk E, et al.
Publicado: (2019)

Hematological toxicities in PARP inhibitors: A real‐world study using FDA adverse event reporting system (FAERS) database
por: Shu, Yamin, et al.
Publicado: (2022)

Adverse events associated with molnupiravir: a real-world disproportionality analysis in food and drug administration adverse event reporting system
por: Liang, Yankun, et al.
Publicado: (2023)

A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib
por: Yin, Yanchao, et al.
Publicado: (2022)

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib
por: Guo, Menglin, et al.
Publicado: (2022)

Assessing real-world safety concerns of Sacituzumab govitecan: a disproportionality analysis using spontaneous reports in the FDA adverse event reporting system
por: Gui, Xiujuan, et al.
Publicado: (2023)

Serious Adverse Drug Events Reported to the FDA: Analysis of the FDA Adverse Event Reporting System 2006-2014 Database
por: Sonawane, Kalyani B., et al.
Publicado: (2018)

Antibiotics and antibiotic-associated diarrhea: a real-world disproportionality study of the FDA adverse event reporting system from 2004 to 2022
por: Huang, Haining, et al.
Publicado: (2023)

A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for venetoclax
por: Yang, Yang, et al.
Publicado: (2022)

Assessing taxane-associated adverse events using the FDA adverse event reporting system database
por: Lao, Dong-Hui, et al.
Publicado: (2021)

Safety Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System
por: Huang, Jing, et al.
Publicado: (2020)

Ovary and uterus related adverse events associated with statin use: an analysis of the FDA Adverse Event Reporting System
por: Jiao, Xue-feng, et al.
Publicado: (2020)

A real-world disproportionality analysis of Rucaparib: Post-marketing Pharmacovigilance Data
por: Zhang, Qilin, et al.
Publicado: (2023)

Adverse Events Associated with Fosfomycin Use: Review of the Literature and Analyses of the FDA Adverse Event Reporting System Database
por: Iarikov, Dmitri, et al.
Publicado: (2015)

Statin-Associated Muscular and Renal Adverse Events: Data Mining of the Public Version of the FDA Adverse Event Reporting System
por: Sakaeda, Toshiyuki, et al.
Publicado: (2011)

Glucagon-like peptide-1 receptor agonists are not associated with retinal adverse events in the FDA Adverse Event Reporting System
por: Fadini, Gian Paolo, et al.
Publicado: (2018)

Comparison of the adverse event profiles of conventional and liposomal formulations of doxorubicin using the FDA adverse event reporting system
por: Fukuda, Akiho, et al.
Publicado: (2017)

Ocular adverse events associated with anti-VEGF therapy: A pharmacovigilance study of the FDA adverse event reporting system (FAERS)
por: Ma, Pan, et al.
Publicado: (2022)

Indication and adverse event profiles of denosumab and zoledronic acid: based on U.S. FDA adverse event reporting system (FAERS)
por: Su, Si, et al.
Publicado: (2023)

Combining Social Media and FDA Adverse Event Reporting System to Detect Adverse Drug Reactions
por: Li, Ying, et al.
Publicado: (2020)

Data Mining of the Public Version of the FDA Adverse Event Reporting System
por: Sakaeda, Toshiyuki, et al.
Publicado: (2013)

EPH43 Potential Association of Remdesivir and Hyperkalemia: A Disproportionality Analysis in USFDA Adverse Event Reporting System Database
por: Das, A., et al.
Publicado: (2023)

Hyperuricaemia, gout and related adverse events associated with antihypertensive drugs: A real-world analysis using the FDA adverse event reporting system
por: Jiao, Xue-Feng, et al.
Publicado: (2023)

Carfilzomib-induced Cardiotoxicity: An Analysis of the FDA Adverse Event Reporting System (FAERS)
por: Buck, Benjamin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_t38ek3bfjf8aieh8pbnmg52shq